Amplia Therapeutics Valuation
| INNMF Stock | USD 0.06 0.01 14.49% |
Amplia Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model approximates the value of Amplia Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.33, profit margin of (1.75) %, and Current Valuation of 4.82 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Amplia Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Amplia Therapeutics is based on 3 months time horizon. Increasing Amplia Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Amplia pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Amplia Therapeutics Limited. Since Amplia Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Amplia Pink Sheet. However, Amplia Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.059 | Real 0.0566 | Hype 0.06 | Naive 0.0555 |
The real value of Amplia Pink Sheet, also known as its intrinsic value, is the underlying worth of Amplia Therapeutics Company, which is reflected in its stock price. It is based on Amplia Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Amplia Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Amplia Therapeutics Limited helps investors to forecast how Amplia pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amplia Therapeutics more accurately as focusing exclusively on Amplia Therapeutics' fundamentals will not take into account other important factors: Amplia Therapeutics Total Value Analysis
Amplia Therapeutics Limited is currently expected to have takeover price of 4.82 M with market capitalization of 12.13 M, debt of 2.1 M, and cash on hands of 14.61 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Amplia Therapeutics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.82 M | 12.13 M | 2.1 M | 14.61 M |
Amplia Therapeutics Investor Information
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.6. Some equities with similar Price to Book (P/B) outperform the market in the long run. Amplia Therapeutics recorded a loss per share of 0.02. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 30th of April 2018. Based on the key indicators related to Amplia Therapeutics' liquidity, profitability, solvency, and operating efficiency, Amplia Therapeutics Limited is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.Amplia Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Amplia Therapeutics has an asset utilization ratio of 12.21 percent. This implies that the Company is making $0.12 for each dollar of assets. An increasing asset utilization means that Amplia Therapeutics Limited is more efficient with each dollar of assets it utilizes for everyday operations.Amplia Therapeutics Ownership Allocation
Amplia Therapeutics holds a total of 194.01 Million outstanding shares. Amplia Therapeutics Limited retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Amplia Therapeutics Profitability Analysis
The company reported the revenue of 2.99 M. Net Loss for the year was (3.64 M) with profit before overhead, payroll, taxes, and interest of 1.83 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Amplia Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Amplia Therapeutics and how it compares across the competition.
About Amplia Therapeutics Valuation
The pink sheet valuation mechanism determines Amplia Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Amplia Therapeutics. We calculate exposure to Amplia Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Amplia Therapeutics's related companies.Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase inhibitors for oncology and chronic fibrosis in Australia. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia. Innate Immunotherapeuti is traded on OTC Exchange in the United States.
8 Steps to conduct Amplia Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Amplia Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Amplia Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Amplia Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Amplia Therapeutics' revenue streams: Identify Amplia Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Amplia Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Amplia Therapeutics' growth potential: Evaluate Amplia Therapeutics' management, business model, and growth potential.
- Determine Amplia Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Amplia Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Amplia Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Amplia Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 193.9 M | |
| Retained Earnings | -128.6 M |
Complementary Tools for Amplia Pink Sheet analysis
When running Amplia Therapeutics' price analysis, check to measure Amplia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amplia Therapeutics is operating at the current time. Most of Amplia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amplia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amplia Therapeutics' price. Additionally, you may evaluate how the addition of Amplia Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |